Carisma Therapeutics to Present at Upcoming Conferences
PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the following upcoming conferences:
Baird 2024 Global Healthcare Conference
- Tuesday, September 10 at 12:50 PM ET
- New York, NY
H.C. Wainwright 26th Annual Global Investment Conference
- Wednesday, September 11 at 1:30 PM ET
- New York, NY
Chardan's 8th Annual Genetic Medicines Conference
- Monday, September 30 at 4:00 PM ET
- New York, NY
The Cell & Gene Meeting on the Mesa
- Monday, October 7 at 9:30 AM MST
- Phoenix, AZ
Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts, when available, will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-conferences-302235237.html
SOURCE Carisma Therapeutics Inc.
Ausgewählte Hebelprodukte auf Carisma Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Carisma Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Carisma Therapeutics Aktie News
Carisma Therapeutics Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Carisma Therapeutics nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.
